Your browser doesn't support javascript.
loading
17ß-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer.
Drula, Rares; Pardini, Barbara; Fu, Xiao; De Los Santos, Mireia Cruz; Jurj, Ancuta; Pang, Lan; El-Daly, Sherien M; Fabris, Linda; Knutsen, Erik; Dragomir, Mihnea P; Bayraktar, Recep; Li, Yongfeng; Chen, Meng; Del Vecchio, Filippo; Berland, Léa; Dae, Jessica; Fan, Daniel; Shimizu, Masayoshi; Tran, Anh M; Barzi, Mercedes; Pioppini, Carlotta; Gutierrez, Angelica M; Ivan, Cristina; Meas, Salyna; Hall, Carolyn S; Alahari, Suresh K; Berindan-Neagoe, Ioana; Fabbri, Muller; Lucci, Anthony; Arun, Banu; Anfossi, Simone; Calin, George A.
Afiliação
  • Drula R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Pardini B; The Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj Napoca, Romania.
  • Fu X; Italian Institute for Genomic Medicine, c/o FPO-IRCCS Candiolo, 10060 Candiolo, Italy.
  • De Los Santos MC; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
  • Jurj A; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Pang L; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061 Shaanxi, China.
  • El-Daly SM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Fabris L; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, 17164 Solna, Sweden.
  • Knutsen E; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Dragomir MP; The Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj Napoca, Romania.
  • Bayraktar R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Li Y; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Chen M; Medical Biochemistry Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo 12622, Egypt.
  • Del Vecchio F; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Berland L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Dae J; Department of Medical Biology, Faculty of Health Sciences, UiT, The Artic University of Norway, N-9037 Tromso, Norway.
  • Fan D; Centre for Clinical Research and Education, University Hospital of North Norway, N-9037 Tromso, Norway.
  • Shimizu M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Tran AM; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10178 Berlin, Germany.
  • Barzi M; German Cancer Research Center (DKFZ), Partner Site Berlin, and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
  • Pioppini C; Berlin Institute of Health, 10178 Berlin, Germany.
  • Gutierrez AM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Ivan C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Meas S; Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022 Zhejiang, P.R. China.
  • Hall CS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Alahari SK; University of Hawaii Cancer Center, Cancer Biology Program, Honolulu, HI 96813.
  • Berindan-Neagoe I; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Fabbri M; Department of Research Imaging, Dana Farber Cancer Institute, Boston, MA 02215.
  • Lucci A; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Arun B; College of Natural Sciences, The University of Texas at Austin, Austin, TX 78712.
  • Anfossi S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Calin GA; College of Natural Sciences, The University of Texas at Austin, Austin, TX 78712.
Proc Natl Acad Sci U S A ; 120(23): e2122053120, 2023 06 06.
Article em En | MEDLINE | ID: mdl-37252969
ABSTRACT
The causes and consequences of abnormal biogenesis of extracellular vesicles (EVs) are not yet well understood in malignancies, including in breast cancers (BCs). Given the hormonal signaling dependence of estrogen receptor-positive (ER+) BC, we hypothesized that 17ß-estradiol (estrogen) might influence EV production and microRNA (miRNA) loading. We report that physiological doses of 17ß-estradiol promote EV secretion specifically from ER+ BC cells via inhibition of miR-149-5p, hindering its regulatory activity on SP1, a transcription factor that regulates the EV biogenesis factor nSMase2. Additionally, miR-149-5p downregulation promotes hnRNPA1 expression, responsible for the loading of let-7's miRNAs into EVs. In multiple patient cohorts, we observed increased levels of let-7a-5p and let-7d-5p in EVs derived from the blood of premenopausal ER+ BC patients, and elevated EV levels in patients with high BMI, both conditions associated with higher levels of 17ß-estradiol. In brief, we identified a unique estrogen-driven mechanism by which ER+ BC cells eliminate tumor suppressor miRNAs in EVs, with effects on modulating tumor-associated macrophages in the microenvironment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs / Vesículas Extracelulares Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs / Vesículas Extracelulares Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2023 Tipo de documento: Article